DDInter1078 DDInter1376
Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved by Health Canada in February 2009. Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal space.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Lisdexamfetamine {u} (Compound) resembles {v} (Compound) Lacosamide
Lisdexamfetamine {u} (Compound) resembles {v} (Compound) Amphetamine
Lisdexamfetamine {u} (Compound) binds {v} (Gene) SLC6A3
Lisdexamfetamine {u} (Compound) palliates {v} (Disease) attention deficit hyperactivity disorder
Lisdexamfetamine {u} (Compound) is included by {v} (Pharmacologic Class) Central Nervous System Stimulation
Lisdexamfetamine {u} (Compound) causes {v} (Side Effect) Psychotic disorder
Lisdexamfetamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lisdexamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Lisdexamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ammonium chloride
Lisdexamfetamine {u} may lead to a major life threatening interaction when taken with {v} Arsenic trioxide
Lisdexamfetamine (Compound) resembles Lacosamide (Compound)
Lisdexamfetamine (Compound) resembles Amphetamine (Compound)
Lisdexamfetamine (Compound) binds SLC6A3 (Gene)
Lisdexamfetamine (Compound) palliates attention deficit hyperactivity disorder (Disease)
Lisdexamfetamine (Compound) is included by Central Nervous System Stimulation (Pharmacologic Class)
Lisdexamfetamine (Compound) causes Psychotic disorder (Side Effect)
Lisdexamfetamine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Ammonium chloride
Lisdexamfetamine may lead to a major life threatening interaction when taken with Arsenic trioxide